ICR Divisions
Collections in this community
Recent submissions
-
Using proton beam therapy to reduce the toxicity of treatment for breast cancer
(Institute of Cancer Research (University Of London), 2024-06-27)Background and purpose Proton beam therapy (PBT) can deliver radiation dose that conforms more closely to the target than photon treatment, sparing organsat-risk {OAR) thereby reducing late effects of radiotherapy ... -
Is There a Special Role for Ovarian Hormones in the Pathogenesis of Lobular Carcinoma?
(ENDOCRINE SOC, 2024-03-29)Lobular carcinoma represent the most common special histological subtype of breast cancer, with the majority classed as hormone receptor positive. Rates of invasive lobular carcinoma in postmenopausal women have been seen ... -
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer
(WILEY, 2024-06-01)<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Elevated circulating growth differentiation factor (GDF15/MIC‐1), interleukin 4 (IL4), and IL6 levels were associated with resistance ... -
Best Overall Response-Associated Signature to Doxorubicin in Soft Tissue Sarcomas: A Transcriptomic Analysis from ANNOUNCE.
(AMER ASSOC CANCER RESEARCH, 2024-06-03)PURPOSE: This exploratory analysis evaluated the tumor samples of the patients treated with doxorubicin (with or without olaratumab) in a negative phase III ANNOUNCE trial to better understand the complexity of advanced ... -
Influence of modern imaging techniques on management of locally and oligometastatic recurrent prostate cancer with Stereotactic Radiotherapy
(Institute of Cancer Research (University Of London), 2024-06-17)Evaluation of the role of novel imaging techniques in the utilisation of stereotactic radiotherapy for recurrent prostate cancer. The current evidence surrounding the diagnosis, management, and areas of clinical need ... -
Elucidating Taxane treatment resistance in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2024-06-17)Despite diagnostic and therapeutic advances, prostate cancer remains the most commonly diagnosed cancer in men, with over 1.2 million new cases worldwide and 20% of cancer-related deaths in men. While initial androgen ... -
Herding clonal evolution to overcome drug resistance in high-grade serous ovarian cancer
(Institute of Cancer Research (University Of London), 2024-06-04)Ovarian cancer (OC) is one of the most common malignancies responsible for cancer-related deaths in women, and finding new treatment strategies is an area of unmet clinical need. To investigate how the concepts of cancer ... -
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives.
(ELSEVIER SCI LTD, 2024-06-01)BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) presents an ideal scenario for intratumoral therapies (IT), due to its local recurrence pattern and frequent superficial extension. IT therapies aim to effect tumor ... -
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies.
(ELSEVIER SCI LTD, 2024-05-26)INTRODUCTION: There is a need to improve the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), especially in recurrent unresectable and metastatic (R/M) setting. ... -
A comprehensive examination of mental health in patients with head and neck cancer: systematic review and meta-analysis.
(OXFORD UNIV PRESS, 2024-04-30)BACKGROUND: Patients with head and neck cancer present particularly considerable levels of emotional distress. However, the actual rates of clinically relevant mental health symptoms and disorders among this population ... -
Investigating the temporal dynamics of T cells following cancer immunotherapy
(Institute of Cancer Research (University Of London), 2024-05-30)The blockade of immune checkpoints PD1 and CTLA4 have become a standard treatment for the treatment of melanoma. However, mechanistic understanding of how the immunotherapy works remains to be achieved. It is largely unknown ... -
Workshop report: the clinical application of data from multiplex assays of variant effect (MAVEs), 12 July 2023.
(SPRINGERNATURE, 2024-05-01)Clinical classification of genomic variants identified on sequencing is often challenging, with many variants classified as Variants of Uncertain Significance (VUS) on account of insufficient evidence. Advances in sequencing ... -
Structural basis for the modulation of MRP2 activity by phosphorylation and drugs.
(NATURE PORTFOLIO, 2024-03-04)Multidrug resistance-associated protein 2 (MRP2/ABCC2) is a polyspecific efflux transporter of organic anions expressed in hepatocyte canalicular membranes. MRP2 dysfunction, in Dubin-Johnson syndrome or by off-target ... -
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
(SPRINGER, 2024-03-02)BACKGROUND: Selective biomarkers may improve outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitor therapy. We investigated three ... -
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
(ELSEVIER, 2024-03-01)The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as ... -
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
(MDPI, 2024-03-04)This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative ... -
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
(Elsevier BV, 2024-03-01)For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an ... -
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT.
(NIHR JOURNALS LIBRARY, 2024-03-01)BACKGROUND: Neutropenic sepsis is a common complication of systemic anticancer treatment. There is variation in practice in timing of switch to oral antibiotics after commencement of empirical intravenous antibiotic therapy. ... -
Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
(American Society of Clinical Oncology (ASCO), 2024-03-01)PURPOSE: Accurate understanding of the genomic and transcriptomic data provided by next-generation sequencing (NGS) is essential for the effective utilization of precision oncology. Molecular tumor boards (MTBs) aim to ...